AR052544A1 - DERIVATIVE OF QUINOLINA, ITS USE, PREPARATION AND MEDICINAL PRODUCT CONTAINING IT - Google Patents

DERIVATIVE OF QUINOLINA, ITS USE, PREPARATION AND MEDICINAL PRODUCT CONTAINING IT

Info

Publication number
AR052544A1
AR052544A1 ARP050105485A ARP050105485A AR052544A1 AR 052544 A1 AR052544 A1 AR 052544A1 AR P050105485 A ARP050105485 A AR P050105485A AR P050105485 A ARP050105485 A AR P050105485A AR 052544 A1 AR052544 A1 AR 052544A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
heteroaryl
independently
aryl
Prior art date
Application number
ARP050105485A
Other languages
Spanish (es)
Inventor
Dominique Schweizer
Laak Antonius Marinus Ter
Stefan Jaroch
Benjamin Bader
Roman Hillig
Dieter Zopf
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of AR052544A1 publication Critical patent/AR052544A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de los compuestos de la formula general A para el tratamiento de diversas enfermedades, así como a la preparacion de compuestos de la formula general A. Reivindicacion 1: Derivado de quinolina de la formula general A en donde A está seleccionado del grupo que comprende -arilo C6-12, - heteroarilo C5-18, -cicloalquilo C3-12 y -heterocicloalquilo C3-12; R1 y R2 son iguales o diferentes y están seleccionados, una o varias veces independientemente entre sí, del grupo que comprende H, hidroxi, halogeno, nitro, ciano, -alquilo C1-6, -hidroxi-alquilo C1-4, - alquenilo C2-6, -alquinilo C2-6, -cicloalquilo C3-10, heterocicloalquilo C3-12, -arilo C6-12, -heteroarilo C5-18, -alcoxi C1-6, -alcoxi c1-6- alcoxi c1-6, -alcoxi C1-6-alquilo C1-6, -alcoxi C1-6-alcoxi C1-6-alquilo C1-6, -(CH2)n-arilo C6-12, -(CH2)n-heteroarilo C5-18, -(CH2)n- cicloalquilo C3-10, -(CH2)n-heterocicloalquilo C3-12, -fenilen-(CH2)p-R6, -(CH2)pPO3(R6)2, -(CH2)p-NR4S(O)R5, -(CH2)p-NR4S(O)2R5, -(CH2)p- NR4CONR5R6, -(CH2)p-NR4COOR5, -(CH2)p-NR4C(NH)NR5R6, -(CH2)p-NR4CSNR5R6, -(CH2)p-NR4S(O)NR5R6, -(CH2)p- NR4S(O)23NR5R6, -(CH2)p-COR5, -(CH2)p-CSR5, -(CH2)p-S(O)R5, -(CH2)p-S(O)(NH)R5, -(CH2)p-S(O)2R5, -(CH2)p-S(O)2NR5R6, -(CH2)p-SO2OR5, -(CH2)p- CO2R5, -(CH2)p-CONR5R6, -(CH2)p-CSNR5R6, -OR5, -(CH2)p-SR5 y -CR5(OH)-R6, en donde -alquilo C1-6, -alquenilo C2-6, -alquinilo C2-6, -cicloalquilo C3-10, -heterocicloalquilo C3-12, -arilo C6-12, -heteroarilo C5-18 y/o -alcoxi c1-6 no están sustituidos o están sustituidos, una o varias veces independientemente entre sí, con hidroxi, halogeno, nitro, ciano, fenilo, -NR5R6, alquilo y/u -OR5, en donde la estructura del C del -cicloalquilo C3-10 y del -alquilo C1-10 puede contener, una o varias veces independientemente entre sí, átomos de N, O, S y/o grupos C=O y/o uno o varios enlaces dobles, y/o R1 y R2 forman opcionalmente entre sí un puente de 3-10 unidades de metileno, en donde hasta dos unidades de metileno se reemplazan opcionalmente con O, S y/o -NR4; X, Y, Z, son iguales o diferentes y están seleccionados, independientemente entre sí, del grupo que comprende -CR3=, -CR3R4-, -C(O)-, -N=, -S-, -O-, -NR3-, -S(O)2-, -S(O)- y -S(O)NH-, y se hallan entre X, Y y Z enlaces simples o dobles; R3 es H, -alquilo C1-10 o -alcanoílo C1-10; R4 es H o -alquilo C1-10; R5 y R6 son iguales o diferentes y están seleccionados, independientemente entre sí, del grupo que comprende H, -alquilo C1-10, -alquenilo C2-10, - alquinilo C2-10, -alcoxi C1-6, -cicloalquilo C3-10, -heterocicloalquilo C3-12, -arilo C6-12 y -heteroarilo C5-18, en donde -alquilo C1-10, -alquenilo C2-10, -alquinilo C2-10, -alcoxi C1-6, -cicloalquilo C3-10, - heterocicloalquilo C3-12, -arilo C6- 12 y/o -heteroarilo C5-18 no están sustituidos o están mono- o polisustituidos independientemente entre sí con hidroxi, halogeno, ciano, nitro, -OR7, -NR7R8, -C(O)NR7R8, -C(O)OR7 y/o -alquilo C1-6, en donde -alquilo c1-6 no está sustituido o está mono- o polisustituido independientemente entre sí con halogeno, hidroxi, ciano, -NR7R8, -OR7 y/o fenilo; y/o R5 y R6 forman opcionalmente entre sí un puente de 3-10 unidades de metileno, en donde hasta dos unidades de metileno se reemplazan opcionalmente con O, S y/o NR4; R7, R8 son iguales o diferentes y están seleccionados, independientemente entre sí, del grupo que comprende H, -alquilo c1-4, -arilo C6-12 y -heteroarilo C5-18, en donde alquilo, arilo, heteroarilo no está sustituido o está sustituido, una o varias veces independientemente entre sí, con y/o alcoxi, o R7 y R8 forman opcionalmente entre sí un puente de 3-10 unidades de metileno, en donde hasta dos unidades de metileno se reemplazan opcionalmente con O, S y/o - NR4;m', mö = independientemente entre sí 0-4; n = 1-6, p = 0-6, así como sus N-oxidos, solvatos, hidratos, estereoisomeros, diastereoisomeros, enantiomeros y sales con la condicion de que, cuando X, Y, Z significan independientemente entre sí 1, 2 o 3 N, 1) el esqueleto del subgrupo X-Y-Z no sea N- CH-N, CH-N-N o -N-N-N y 2) X no sea NH cuando Y y Z son al mismo tiempo CH.Use of the compounds of the general formula A for the treatment of various diseases, as well as the preparation of compounds of the general formula A. Claim 1: Quinoline derivative of the general formula A wherein A is selected from the group comprising - C6-12 aryl, - C5-18 heteroaryl, - C3-12 cycloalkyl and - C3-12 heterocycloalkyl; R1 and R2 are the same or different and are selected, once or several times independently from each other, from the group comprising H, hydroxy, halogen, nitro, cyano, -C 1-6 alkyl, -hydroxy-C 1-4 alkyl, - C 2 alkenyl -6, -C2-6alkynyl, -C3-10cycloalkyl, C3-12 heterocycloalkyl, -C6-12 -aryl, -C5-18 heteroaryl, -C1-6 alkoxy, -C1-6 alkoxy-C1-6 alkoxy, - C1-6 alkoxy-C1-6 alkyl, -C 1-6 alkoxy-C1-6 alkoxy-C1-6 alkyl, - (CH2) n-aryl C6-12, - (CH2) n-heteroaryl C5-18, - ( CH2) n- C3-10 cycloalkyl, - (CH2) n-heterocycloalkyl C3-12, -phenylene- (CH2) p-R6, - (CH2) pPO3 (R6) 2, - (CH2) p-NR4S (O) R5, - (CH2) p-NR4S (O) 2R5, - (CH2) p- NR4CONR5R6, - (CH2) p-NR4COOR5, - (CH2) p-NR4C (NH) NR5R6, - (CH2) p-NR4CSNR5R6, - (CH2) p-NR4S (O) NR5R6, - (CH2) p- NR4S (O) 23NR5R6, - (CH2) p-COR5, - (CH2) p-CSR5, - (CH2) pS (O) R5, - (CH2) pS (O) (NH) R5, - (CH2) pS (O) 2R5, - (CH2) pS (O) 2NR5R6, - (CH2) p-SO2OR5, - (CH2) p- CO2R5, - (CH2) p-CONR5R6, - (CH2) p-CSNR5R6, -OR5, - (CH2) p-SR5 and -CR5 (OH) -R6, where -C1-6 alkyl, -C2-6 alkenyl, -alkynyl C2-6, -C3-10 cycloalkyl, -C3-12 heterocycloalkyl, -C6-12 -aryl, -C5-18 heteroaryl and / or -C1-6 alkoxy are not substituted or substituted, once or several times independently of each other, with hydroxy, halogen , nitro, cyano, phenyl, -NR5R6, alkyl and / or -OR5, wherein the C structure of the C3-10 cycloalkyl and the C1-10 alkyl can contain, once or several times independently of each other, N atoms , O, S and / or groups C = O and / or one or several double bonds, and / or R1 and R2 optionally form a bridge of 3-10 methylene units, where up to two methylene units are optionally replaced with O, S and / or -NR4; X, Y, Z, are the same or different and are independently selected from the group comprising -CR3 =, -CR3R4-, -C (O) -, -N =, -S-, -O-, - NR3-, -S (O) 2-, -S (O) - and -S (O) NH-, and single or double bonds are between X, Y and Z; R3 is H, -C1-10 alkyl or -C1-10 alkanoyl; R4 is H or -C1-10 alkyl; R5 and R6 are the same or different and are independently selected from the group comprising H, -C1-10 alkyl, -C2-10 alkenyl, -C2-10 alkynyl, -C1-6 alkoxy, -C3-10 -cycloalkyl , -C3-12 heterocycloalkyl, -C6-12 -aryl and -C5-18 heteroaryl, wherein -C1-10 alkyl, -C2-10 alkenyl, -C2-10 alkynyl, -C1-6 alkoxy, -C3-10 -cycloalkyl , - C3-12 heterocycloalkyl, C6-12 -aryl and / or -C5-18 heteroaryl are not substituted or are mono- or polysubstituted independently of each other with hydroxy, halogen, cyano, nitro, -OR7, -NR7R8, -C ( O) NR7R8, -C (O) OR7 and / or -C1-6 alkyl, wherein -C1-6 alkyl is not substituted or is mono- or polysubstituted independently of one another with halogen, hydroxy, cyano, -NR7R8, -OR7 and / or phenyl; and / or R5 and R6 optionally form a bridge of 3-10 methylene units with each other, where up to two methylene units are optionally replaced with O, S and / or NR4; R7, R8 are the same or different and are independently selected from the group comprising H, -C1-4 alkyl, -C6-12 alkyl and -C5-18 heteroaryl, wherein alkyl, aryl, heteroaryl is unsubstituted or is substituted, once or several times independently of each other, with and / or alkoxy, or R7 and R8 optionally form a bridge of 3-10 methylene units, where up to two methylene units are optionally replaced with O, S and / o - NR4; m ', mö = independently from each other 0-4; n = 1-6, p = 0-6, as well as their N-oxides, solvates, hydrates, stereoisomers, diastereoisomers, enantiomers and salts with the proviso that, when X, Y, Z independently mean each other 1, 2 or 3 N, 1) the skeleton of subgroup XYZ is not N-CH-N, CH-NN or -NNN and 2) X is not NH when Y and Z are at the same time CH.

ARP050105485A 2004-12-22 2005-12-22 DERIVATIVE OF QUINOLINA, ITS USE, PREPARATION AND MEDICINAL PRODUCT CONTAINING IT AR052544A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004063223A DE102004063223A1 (en) 2004-12-22 2004-12-22 New quinoline derivatives are ephrin receptor kinase inhibitors useful for the treatment of e.g. blood vessels diseases, hyperproliferations, chronic or acute neurodegenerative diseases, psoriasis, eczema and scleroderma

Publications (1)

Publication Number Publication Date
AR052544A1 true AR052544A1 (en) 2007-03-21

Family

ID=36599298

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105485A AR052544A1 (en) 2004-12-22 2005-12-22 DERIVATIVE OF QUINOLINA, ITS USE, PREPARATION AND MEDICINAL PRODUCT CONTAINING IT

Country Status (7)

Country Link
CN (1) CN101087788A (en)
AR (1) AR052544A1 (en)
DE (1) DE102004063223A1 (en)
GT (1) GT200500381A (en)
PA (1) PA8657701A1 (en)
SV (1) SV2007002357A (en)
UY (1) UY29308A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103382206B (en) * 2012-05-04 2016-09-28 上海恒瑞医药有限公司 Quinoline or quinazoline derivative, its preparation method and in application pharmaceutically
CN106565823B (en) * 2016-11-10 2020-09-11 珠海诺贝尔国际生物医药研究院有限公司 Eph receptor small molecule inhibitor and preparation method thereof
WO2019233458A1 (en) * 2018-06-08 2019-12-12 江苏威凯尔医药科技有限公司 Vegfr inhibitor, preparation method therefor and use thereof
CN110577546B (en) * 2018-06-08 2021-09-07 江苏威凯尔医药科技有限公司 VEGFR inhibitor and preparation method and application thereof
CN113150009B (en) * 2020-01-07 2023-05-23 爱科诺生物医药(香港)有限公司 Heterocyclic compound with activity of inhibiting programmed cell necrosis pathway and application thereof
CN113061142A (en) * 2020-01-02 2021-07-02 爱科诺生物医药股份有限公司 Heterocyclic compounds with programmed cell necrosis pathway inhibition activity and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3919238A (en) * 1973-06-06 1975-11-11 Morton Norwich Products Inc 9-(Substituted amino)imidazo(4,5-f) quinolines
CA1263378A (en) * 1985-01-08 1989-11-28 Robert James Alaimo Imidazo¬4,5-f|quinolines useful as immunomodulating agents
JPH06504294A (en) * 1991-08-02 1994-05-19 ファイザー・インコーポレーテッド Quinoline derivatives as immunostimulants

Also Published As

Publication number Publication date
CN101087788A (en) 2007-12-12
DE102004063223A1 (en) 2006-07-13
PA8657701A1 (en) 2006-09-08
UY29308A1 (en) 2006-06-30
SV2007002357A (en) 2007-02-16
GT200500381A (en) 2006-08-03

Similar Documents

Publication Publication Date Title
PE20180462A1 (en) TOC MODULATORS AND METHODS OF USING THEM
PE20021010A1 (en) SPIROCYCLIC DERIVATIVES AS PHOSPHODIESTERASE-7 INHIBITORS
ECSP088590A (en) MULTICYCLIC AMINO ACID DERIVATIVES AND THEIR METHODS OF USE
PE20142456A1 (en) OXAZOLIDIN-2-ONA COMPOUNDS AND USES OF THE SAME AS INHIBITORS OF PI3Ks
AR052544A1 (en) DERIVATIVE OF QUINOLINA, ITS USE, PREPARATION AND MEDICINAL PRODUCT CONTAINING IT
AR078786A1 (en) CHROMENONE DERIVATIVES
AR044078A1 (en) SUBSTITUTED DIHYDROQUINAZOLINS
CO5680439A2 (en) CYCLOTIOCARBAMATE DERIVATIVES AS PR MODULATORS AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS
DE602006006850D1 (en) AZABICYCLO (3,1,0) -HEXAN DERIVATIVES SUITABLE AS MODULATORS OF DOPAMINE D3 RECEPTORS
UY29469A1 (en) SULFOXIMINO-MACROCYCLIC COMPOUNDS AND THEIR SALTS, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH COMPOUNDS, PREPARATION METHODS AND USES OF THE SAME.
AR041347A1 (en) IMIDAZOL DERIVATIVES [1,2-A] PIRAZINAS AS INHIBITORS OF CYCLINE DEPENDENT KINASES
AR054035A1 (en) BENZODIOXAN AND BENZODIOXOLAN DERIVATIVES AND USE OF THE SAME
ECSP099394A (en) DERIVATIVES OF QUINUCLIDINOL AS ANTOGONISTS OF MUSCARINIC RECEPTORS
AR072906A1 (en) MODIFIED NUCLEOSIDS USEFUL AS ANTIVIRAL
AR072791A1 (en) DERIVATIVES OF TIAZOLIDIN-2, 4-DIONA, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THEIR USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER.
AR040806A1 (en) DERIVATIVES OF PIPERIDI-2-ONA 1.6 DISUSTITUTED, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT AND TREATMENT METHOD
AR080785A1 (en) DERIVATIVES OF IMIDAZO [1,2-A] PYRIMIDINE, PROCESS TO PREPARE THEM AND INTERMEDIARIES OF SUCH SYNTHESIS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THEM IN THE TREATMENT OF PATHOLOGIES OF THE CENTRAL NERVOUS SYSTEM, SUCH AS PARK AND OTHERS.
AR085406A1 (en) N-SUBSTITUTED OXAZINOPTERIDINS AND N-REPLACED OXAZINOPTERIDINONES
AR056511A1 (en) DERIVATIVES OF 2-AMINOPIRIMIDINES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY THE HISTAMINE RECEIVER H4
AR048028A1 (en) 5,6-DIALQUIL-7-AMINO-TRIAZOLOPIRIMIDINAS, PROCEDURES FOR THEIR PREPARATION AND THE USE OF THE SAME TO COMBAT HARMFUL FUNGES, AS WELL AS PRODUCTS CONTAINING THEM
UY29002A1 (en) NEW HIDANTOINE DERIVATIVES, PARASU PREPARATION PROCESSES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THERAPY
UY29732A1 (en) BENZOTIAZOLONAS DERIVATIVES, PREPARATION PROCESSES, COMPOSITIONS AND COMBINATIONS CONTAINING THEM AND APPLICATIONS
UY29003A1 (en) NEW HIDANTOINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THERAPY
AR059032A1 (en) COMBINATION OF TRIAZINE DERIVATIVES AND INSULIN SENSITIZERS
UY29070A1 (en) FUSIONED HETEROCYCLIC ENANTIOMERS AND THEIR USES

Legal Events

Date Code Title Description
FA Abandonment or withdrawal